Seminars in oncology · 2002
In vitro studies with bendamustine: enhanced activity in combination with rituximab.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rummel Mathias J, Chow Kai U, Hoelzer Dieter, Mitrou Paris S, Weidmann Eckhart
Аннотация
Studies in vitro have shown that bendamustine, given as a monotherapy or in combination, can induce apoptosis in many cell types, including B-cell chronic lymphocytic leukemia and low-grade lymphoma cells. Evidence is accumulating to suggest that bendamustine may also have synergistic effects in combination therapies. Rituximab is a promising new agent for the treatment of hematologic malignancies and has been shown to have synergistic actions with other chemotherapeutic agents. The actions of the combination of bendamustine and rituximab on ex vivo B-cell chronic lymphocytic leukemia cells and the DOHH-2 cell line, derived from CD20-positive lymphoma cells, are discussed in this article.
Предметные рубрики MeSH
Antibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBendamustine HydrochlorideCarcinomaComplement System ProteinsDrug SynergismHumansLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-HodgkinNitrogen Mustard CompoundsRituximabTumor Cells, Cultured